Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01544569
First received: February 29, 2012
Last updated: March 7, 2012
Last verified: March 2012
  Purpose

RATIONALE: Studying samples of tissue from patients with rhabdoid tumors in the laboratory may help doctor learn more about changes that occur in DNA and identify genes related to cancer.

PURPOSE: This research trial studies biomarkers in samples from young patients with rhabdoid tumors.


Condition Intervention
Kidney Cancer
Genetic: DNA analysis
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: gene mapping
Genetic: microarray analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Other: laboratory biomarker analysis
Other: medical chart review

Study Type: Observational
Official Title: Endogenous DNA Transposition in Rhabdoid Tumors

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Expression and function of PGBD5 in rhabdoid tumors [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To investigate the expression and function of PGBD5 in 50 primary rhabdoid tumors.

OUTLINE: Freshly frozen rhabdoid tumors will be studied using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to establish the genomic location of PGBD5. Protein expression in rhabdoid tumor tissue microarrays is also analyzed.

  Eligibility

Ages Eligible for Study:   up to 1 Year
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Freshly frozen rhabdoid tumors from either renal or extra-renal sites from children younger than 2 years of age
  • Clinical patient information (age, gender, comorbidities, tumor stage, size, pathology, therapy, outcome) available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01544569

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Elizabeth A. Mullen, MD Dana-Farber Cancer Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01544569     History of Changes
Other Study ID Numbers: CDR0000727229, COG-AREN12B3
Study First Received: February 29, 2012
Last Updated: March 7, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
rhabdoid tumor of the kidney

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Rhabdoid Tumor
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms

ClinicalTrials.gov processed this record on November 25, 2014